• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人组织型纤溶酶原激活剂在兔和犬体内的肌肉注射及其对冠状动脉溶栓的意义。

Intramuscular administration of human tissue-type plasminogen activator in rabbits and dogs and its implications for coronary thrombolysis.

作者信息

Sobel B E, Saffitz J E, Fields L E, Myears D W, Sarnoff S J, Robison A K, Owensby D A, Fox K A

出版信息

Circulation. 1987 Jun;75(6):1261-72. doi: 10.1161/01.cir.75.6.1261.

DOI:10.1161/01.cir.75.6.1261
PMID:3105915
Abstract

To determine whether sustained plasma concentration of human tissue-type plasminogen activator (t-PA) can be induced promptly after intramuscular injection with enhancers of absorption devoid of deleterious local and systemic effects, we studied 250 rabbits and 13 dogs. In rabbits with t-PA injected directly into exposed muscle followed by local electrical stimulation at the site, early absorption was increased markedly by addition of 0.63M methylamine plus 0.079M hydroxylamine to the excipient. Elevations peaked within 5 min and increased with dose of t-PA, concentration of methylamine, and volume of injection medium. The enhancers were effective with percutaneous injections in the absence of local electrical stimulation as well. They did not elicit any obviously deleterious local or systemic effects. In separate experiments in rats, intramuscular injections of 0.63M methylamine plus 0.079M hydroxylamine induced local egress of intravascular radiolabeled albumin within the injection site and endothelial gaps in venules detected with colloidal carbon--changes consistent with direct effects on vascular permeability. In dogs, percutaneous intramuscular injection of t-PA in excipient without enhancers did not lead to early elevations of human t-PA in plasma, although late elevations were seen. When the enhancers were used, early elevations occurred as well, with functional activity documented by fibrin plate assays of serially obtained plasma samples and by sequential coronary angiography delineating thrombolysis after experimentally induced coronary thrombosis. The results indicate that intramuscular administration of t-PA with selected enhancers of absorption is a feasible approach for rapid induction of fibrinolysis.

摘要

为了确定在肌肉注射无有害局部和全身作用的吸收增强剂后,能否迅速诱导人组织型纤溶酶原激活剂(t-PA)的持续血浆浓度,我们研究了250只兔子和13只狗。在将t-PA直接注射到暴露肌肉中并随后在该部位进行局部电刺激的兔子中,向赋形剂中添加0.63M甲胺加0.079M羟胺可使早期吸收显著增加。升高在5分钟内达到峰值,并随t-PA剂量、甲胺浓度和注射介质体积的增加而增加。这些增强剂在无局部电刺激的经皮注射中也有效。它们未引起任何明显有害的局部或全身作用。在大鼠的单独实验中,肌肉注射0.63M甲胺加0.079M羟胺可诱导注射部位血管内放射性标记白蛋白的局部渗出以及用胶体碳检测到的小静脉内皮间隙——这些变化与对血管通透性的直接作用一致。在狗中,在赋形剂中经皮肌肉注射无增强剂的t-PA不会导致血浆中人t-PA的早期升高,尽管会出现晚期升高。当使用增强剂时,也会出现早期升高,通过对连续获取的血浆样本进行纤维蛋白平板分析以及通过在实验性诱导冠状动脉血栓形成后进行连续冠状动脉造影描绘溶栓情况来记录功能活性。结果表明,肌肉注射t-PA并使用选定的吸收增强剂是快速诱导纤维蛋白溶解的可行方法。

相似文献

1
Intramuscular administration of human tissue-type plasminogen activator in rabbits and dogs and its implications for coronary thrombolysis.人组织型纤溶酶原激活剂在兔和犬体内的肌肉注射及其对冠状动脉溶栓的意义。
Circulation. 1987 Jun;75(6):1261-72. doi: 10.1161/01.cir.75.6.1261.
2
Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.冠状动脉溶栓与促进肌肉注射组织型纤溶酶原激活剂的吸收
Proc Natl Acad Sci U S A. 1985 Jun;82(12):4258-62. doi: 10.1073/pnas.82.12.4258.
3
Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.组织型纤溶酶原激活剂诱导的实验性冠状动脉溶栓中肝素的需求量:与尿激酶诱导的冠状动脉溶栓的比较。
Jpn Circ J. 1987 Apr;51(4):431-5. doi: 10.1253/jcj.51.431.
4
Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators.肌肉注射组织型纤溶酶原激活剂的分子变体和去糖基化形式后血浆浓度的增强和持续
Circulation. 1990 Apr;81(4):1362-73. doi: 10.1161/01.cir.81.4.1362.
5
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
J Cardiovasc Pharmacol. 1987 Jan;9(1):91-3.
6
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.人组织型纤溶酶原激活剂非糖基化突变体(缺失指状结构域和生长因子结构域)在铜圈诱导的犬冠状动脉血栓形成模型中的药代动力学和溶栓特性
J Cardiovasc Pharmacol. 1988 Apr;11(4):468-72. doi: 10.1097/00005344-198804000-00013.
7
Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
Jpn J Pharmacol. 1993 Nov;63(3):319-25. doi: 10.1254/jjp.63.319.
8
Coronary thrombolysis with tissue-type plasminogen activator (t-PA): emerging strategies.使用组织型纤溶酶原激活剂(t-PA)进行冠状动脉溶栓:新出现的策略。
J Am Coll Cardiol. 1986 Nov;8(5):1220-5. doi: 10.1016/s0735-1097(86)80404-1.
9
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.硝酸甘油联合治疗未能提高组织型纤溶酶原激活剂对冠状动脉血栓形成疗效的病理基础。
Cardiovasc Res. 1991 Apr;25(4):283-9. doi: 10.1093/cvr/25.4.283.
10
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.

引用本文的文献

1
Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.单纯溶栓是急性心肌梗死的最佳治疗方法吗?现状与新策略
Tex Heart Inst J. 1991;18(1):50-61.
2
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.溶栓疗法在急性心肌梗死和不稳定型心绞痛治疗中的应用
Drugs. 1989 Feb;37(2):191-204. doi: 10.2165/00003495-198937020-00006.
3
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.组织型纤溶酶原激活剂。其药理学及作为溶栓剂的治疗用途综述。
Drugs. 1989 Sep;38(3):346-88. doi: 10.2165/00003495-198938030-00003.